

AD \_\_\_\_\_

Award Number: W81XWH-08-1-0639

TITLE: Breast Tumor-Generated Type 1 Collagen Breakdown Fragments  
Act as Matrikines to Drive Osteolysis

PRINCIPAL INVESTIGATOR: Ching Hua William Wu PhD.

CONTRACTING ORGANIZATION: Henry Ford Health System  
Detroit, MI 48202

REPORT DATE: September 2009

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

X Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE (DD-MM-YYYY)</b> 01-09-2009		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED (From - To)</b> 9/01/2008-8/31/2009	
<b>4. TITLE AND SUBTITLE</b>  Breast Tumor-Generated Type 1 Collagen Breakdown Fragments Act as Matrikines to Drive Osteolysis				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b> W81XWH-08-1-0639	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> Ching Hua William Wu PhD  Email: wwul@hfhhs.org				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Henry Ford Health System, Detroit, MI 48202				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  US Army Medical Research and Material Command Fort Detrick, MD 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for public release; distribution unlimited					
<b>13. SUPPLEMENTARY NOTES</b> None					

**14. ABSTRACT**  
The major site of metastasis of breast cancer cells is bone. Bone metastases occur in 80% of patients with advanced disease and causes significant morbidity. The mechanisms of osteolysis and targeting of bone by the breast cancer cells are still unknown. The osteolysis that occurs in patients is mediated by factors that come from the tumor cells. The tumor cells provide a microenvironment to the osteoblasts and osteoclasts. Bone remodeling requires the degradation and turnover of type I collagen. Type I collagen is a triple helical fibrillar collagen that can be cleaved by cathepsin K found only in osteoclasts. Recently, studies of breakdown fragments of extracellular matrix (ECM) proteins have shown novel biological activity of the fragments. We believe that these fragments may be chemotactic to breast tumor cells. Once the breast tumor cells metastasize to the bone, the tumor cells secrete factors that stimulate the increase in osteolysis of bone. This leads to increase of type I collagen fragments that signal back to the tumor cells, osteoblasts and osteoclasts perpetuating this cascade. This study proposes to map the active sequences in the type I collagen breakdown fragments that can contribute to breast tumor metastasis to bone. The understanding of this pathway can lead to development of biomarkers assays to detect early bone metastases, monitor treatments in targeting bone metastases and staging of metastatic bone tumors. Prevention, early detection and treatment of bone metastasis breast tumors to bone would benefit the survival and quality of life of breast cancer patients.

**15. SUBJECT TERMS**  
Bone, Metastasis, Collagen, Proteases

<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>  UU	<b>18. NUMBER OF PAGES</b>  6	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC
<b>a. REPORT</b> U	<b>b. ABSTRACT</b> U	<b>c. THIS PAGE</b> U			<b>19b. TELEPHONE NUMBER (include area code)</b>

**Table of Contents**

**Introduction.....5**

**Body.....5**

**Key Research Accomplishments.....6**

**Reportable Outcomes.....6**

**Conclusions.....7**

**References.....7**

## INTRODUCTION

This study was funded to assess the ability of novel type I collagen degradation fragments that are generated by Cathepsin K cleavage found in osteoclasts to induce the upregulation of inflammatory cytokines (GM-CSF, TNF-alpha, PTHrP, IL-1, and IL-6), in breast tumor cells and osteoblasts, which stimulate osteoclast formation and increase osteolysis.

Bone is an active remodeling tissue and accounts for the major of type I collagen turnover in the body. Once the breast tumor cells metastasize to the bone, the tumor cells secrete inflammatory chemokines and cytokines such as PTHrP, receptor activator of nuclear factor kappa B (RANK) that stimulate osteoclast formation. These events result in increased osteolysis. The increased osteolysis of bone leads to increased type I collagen fragments that signal back to the tumor cells, osteoblasts and osteoclasts perpetuating this cascade.

The major site of metastasis of breast cancer cells is bone. Bone metastases occur in 80% of patients with advanced disease and causes significant morbidity. The mechanisms of osteolysis and targeting of bone by the breast cancer cells are still unknown. The osteolysis that occurs in patients is mediated by factors that come from the tumor cells. The tumor cells provide a microenvironment to the osteoblasts and osteoclasts. Bone remodeling requires the degradation and turnover of type I collagen. Type I collagen is a triple helical fibrillar collagen that can only be cleaved by collagenases of the matrix metalloproteinase (MMP) family or by cathepsin K found only in osteoclasts. The extracellular matrix plays an important role in tissue homeostasis. It regulates cellular differentiation, migration, and proliferation. Recently it has been shown that cleavage products of ECM proteins may have novel biological properties and have been termed matrikines<sup>1, 2</sup>.

The scope of this work includes the characterization of the ability of cathepsin K generated type I collagen cleavage fragments on breast tumor cells to produce inflammatory cytokines and proteases and to characterize the specific sequences in the type I collagen fragments that induce inflammatory cytokines and proteases.

## BODY

In the first 12 months of the project, we projected that we would be able to characterize and identify specific cathepsin K generated type I collagen fragments that would stimulate breast tumor cells to produce inflammatory cytokines and proteases. Below are the objectives from the original statement of work.

### *Tasks*

Specific Aim 1: To characterize the ability of cathepsin K generated type I collagen cleavage fragments on breast tumor cells to produce inflammatory cytokines and proteases.

a) Purification of Type I matrikines:

Native rat type I collagen will be incubated with recombinant cathepsin K at 25°C and pH 5.0 for 6h<sup>3</sup>, cleavage products as described in Kafienah *et al.*<sup>3</sup>, will be separated and purified by SDS-PAGE and HPLC.

b) Testing biological activity of Type I collagen fragments:

Breast tumor cell lines (MCF-10-2A, HCC1500, MDA-MB-231) will be grown *in vitro* and incubated with cathepsin k generated peptides of type I collagen.

Cells will be grown in 12 well plates in triplicate. A dose-response curve will be determined using different concentrations of matrikine fragments.

Cathepsin K, PTHrP, TNF-alpha, GM-CSF, IL-1, IL-6, RANK mRNA levels will be quantitated by Real-Time PCR (ABI -7500) and by human cytokine arrays (R&D, MN).

Cathepsin K protein will be analyzed by Western blotting with rabbit polyclonal antibodies.

Specific Aim 2: Characterize the specific sequences in the type I collagen fragments that induce inflammatory cytokines and proteases.

a) Mapping of specific matrikine sequences in purified type I collagen fragments:

To characterize the active sequences in the collagen fragments, overlapping peptides will be synthesized from bioactive fragments and then tested individually in the tumor cell lines.

b) Testing biological activity of Type I collagen matrikine fragments :

Breast tumor cell lines (MCF-10-2A, HCC1500, MDA-MB-231) will be grown *in vitro* and incubated with cathepsin k generated peptides of type I collagen.

Cells will be grown in 12 well plates in triplicate. A dose-response curve will be determined using different concentrations of matrikine fragments.

Cathepsin K, PTHrP, TNF-alpha, GM-CSF, IL-1, IL-6, RANK mRNA levels will be quantitated by Real-Time PCR (ABI -7500) and by human cytokine arrays (R&D, MN).

Cathepsin K protein will be analyzed by Western blotting with rabbit polyclonal antibodies.

The project was delayed 4 months due to hiring of a new research assistant. The research assistant was recent graduate and had to be trained in new laboratory methods. In the past 3 months we have generated Cathepsin K type I fragments that we have tested on breast tumor lines MCF-10-2A, HCC1500, MDA-MB-231. We have identify 2 regions of in the type I collagen triple helix can stimulate the tumor cells to produce inflammatory cytokines and MMPs. We are now completing the mRNA analysis and designing overlapping synthetic peptides to map the specific matrikine sequences in these 2 regions in the triple helix of type I collagen. When we receive the synthetic peptides we can map the regions and identify and test the specific matrikines on the breast tumor lines.

## KEY RESEARCH ACCOMPLISHMENTS

- Identified 2 regions in type I collagen triple helix that has novel biological activity on breast tumor cells.
- Trained new college graduate in laboratory methods in matrix biology

## REPORTABLE OUTCOMES

Reportable outcomes are expected for the next review.

## CONCLUSIONS

There is increasing evidence that matrix molecules especially collagen and its cleavage products can act as novel matrikines that may play a role in tumor microenvironment, progression and metastasis.

## REFERENCES

1. Tran KT, Lamb P, Deng JS. Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. *J Dermatol Sci.* Oct 2005;40(1):11-20.
2. Maquart FX, Bellon G, Pasco S, Monboisse JC. Matrikines in the regulation of extracellular matrix degradation. *Biochimie.* Mar-Apr 2005;87(3-4):353-360.
3. Kafienah W, Bromme D, Buttle DJ, Croucher LJ, Hollander AP. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. *Biochem J.* May 1 1998;331 ( Pt 3):727-732.